Genentech reports positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common ... Individual.com, 22 hours ago
Ocrelizumab Reduces Relapses and Disability Progression in Pivotal MS Trials - Pharmscope, 2 days ago
Genentech (RHHBY)'s Ocrelizumab Poised to Enter $18 Billion MS Market as Drug Wows in Huge Late-Stage Studies 6/30/2015 - ClinicSpace, 2 days ago
More from: CNBC, Vision Monday...and 43 other sources
Biopharmaceutical company Exelixis (EXEL) Wednesday said its partner Genentech informed that, in order to accommodate its review of a supplemental data submission, the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act ...RTTNews.com, 1 day ago FDA taps the brakes on Genentech's cobimetinib review FierceBiotech, 1 day ago FDA extends review of Roche, Exelixis' melanoma drug cobimetinib by three months FirstWord Pharma, 1 day ago FDA extends PDUFA date for review of cobimetinib NDA; Exelixis off 8% Seeking Alpha, 1 day ago
Genentech Inc., a biotechnology company, has received breakthrough therapy designation status from the FDA for Actemra, indicated for the treatment of systemic sclerosis, also known as scleroderma. "The development of Actemra in systemic sclerosis ...Individual.com, 1 week ago
Exelixis (EXEL) Provides Update On Genentech (RHHBY)'s Pending New Drug Application For Cobimetinib, An Exelixis-Discovered Compound 7/1/2015
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Yesterday, Exelixis (NASDAQ:EXEL) partner Genentech, a member of the Roche Group, informed Exelixis that, in order to accommodate its review of a supplemental data submission, the U.S.ClinicSpace, 1 day ago Exelixis : Provides Update on Genentech's Pending New Drug Application for Cobimetinib, an Exelixis-Discovered Compound 4 Traders, 1 day ago Exelixis Provides Update on Genentech's Pending New Drug Application for Cobimetinib, an Exelixis-Discovered Compound Yahoo! Finance UK and Ireland, 1 day ago
|Securities Technology Monitor, 1 week ago Expert Panel on The New Patient Experience Organized by PRC Clinical at Genentech BizWire Express, 1 week ago|
June 30, 2015 By Mark Terry , BioSpace.com Breaking News Staff South San Francisco, Calif.-based Genentech ( RHHBY ) announced today that its clinical studies of ocrelizumab compared to interferon beta-1a (Rebif) in relapsing multiple ...BioSpace, 2 days ago Genentech (RHHBY)'s Ocrelizumab Wows in Late Stages and Eyes $18 Billion MS Market 7/1/2015 ClinicSpace, 11 hours ago
Studies from Genentech, Inc. Have Provided New Data on Basal Cell Cancer (A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy...
Studies from Genentech, Inc. Have Provided New Data on Basal Cell Cancer (A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma) By a News Reporter-Staff News Editor ...4 Traders, 1 day ago
The web of Genentech Inc. alumni is vast, intersecting and sought out by investors and biotech companies of all sizes. Grab a "Genenexer" for your board of directors or land one for your executive ranks or your science team, then your company wins ...BioSpace, 1 day ago The Power of Being a Genentech (RHHBY) Alumni 7/1/2015 ClinicSpace, 1 day ago
Share this article: Genentech announce positive results from two Phase 3 studies evaluating ocrelizumab compared with Rebif (interferon beta-1a) in patients with relapsing multiple sclerosis (MS) . OPERA I and OPERA II are randomized, ...Monthly Prescribing Reference, 2 days ago AbbVie announces encouraging results from Phase Ib CLL study Individual.com, 1 week ago
Genentech announced the launch of a new trial, GiACTA, of its interleukin-6 inhibitor as a steroid-sparing agent in patients with giant cell arteritis at the European League Against Rheumatism Annual European Congress of Rheumatology. Clinical ...Orthopedics Today, 2 days ago
on your WebpageAdd Widget >Get your members hooked!